Wicker Camille, Roda Célina, Perry Ariane, Arnoux Jean Baptiste, Brassier Anais, Castelle Martin, Servais Aude, Donadieu Jean, Bouchereau Juliette, Pigneur Bénédicte, Labrune Philippe, Ruemmele Frank M, de Lonlay Pascale
Reference Center for Inherited Metabolic Diseases, Necker Hospital, APHP, Filière G2 M, MetabERN, Paris, France.
Paris University, CRESS, HERA (Health Environmental Risk Assessment) team, INSERM, INRA, F-75004 Paris, France.
Mol Genet Metab Rep. 2020 Apr 9;23:100581. doi: 10.1016/j.ymgmr.2020.100581. eCollection 2020 Jun.
Glycogenosis type Ib (GSD1B) causes not only hypoglycemia but also infections and "Crohn's disease like" inflammatory bowel disease (IBD) that can significantly impair patient's quality of life. We retrospectively evaluated infectious and digestive complications in 9 French patients (3 girls, 6 boys) diagnosed at 0.8 years on average, with a mean follow-up of 19.1 years. Infections occurred earlier than IBD, at mean ages of 1.7 and 3.8 years, respectively. The number of acute hospitalizations was 0.7/year due to infectious (0.4/year) or digestive symptoms (0.4/year). Clinical presentations allowed separating patients into mild ( = 5) and severe ( = 4) intestinal involvement. Patients in the severe group had more serious digestive symptoms but also earlier neutropenia (median 0.3 vs. 1.5 years, =0 .046) with a tendency to a lower neutrophil count (NC) during follow-up, and a higher number of acute hospitalizations (median 1.3/year vs. 0.2/year, =0 .014) due to digestive symptoms (median 0.6/year vs. 0.05/year, = 0,012) and infections (median 0.8/year vs. 0.2/year, p =0 .014). Treatments included G-CSF and cotrimoxazole ( = 7), 5-aminosalicylic acid ( = 2), and a polymeric solution enriched in the anti-inflammatory cytokine TGF-β ( = 4, "severe" group), and immunomodulatory treatment ( = 1). In conclusion, infections and IBD are rare but severe complications in GSD1B. Neutropenia tended to be more prevalent in the severe IBD group than in the mild IBD group. Dietetic treatment with specific anti-inflammatory solutions seems particularly appropriate in these patients.
1b型糖原贮积病(GSD1B)不仅会导致低血糖,还会引发感染以及“克罗恩病样”炎症性肠病(IBD),这些会严重损害患者的生活质量。我们回顾性评估了9名法国患者(3名女孩,6名男孩)的感染和消化并发症情况,这些患者平均在0.8岁时被确诊,平均随访时间为19.1年。感染比IBD出现得更早,平均发病年龄分别为1.7岁和3.8岁。由于感染(每年0.4次)或消化症状(每年0.4次)导致的急性住院次数为每年0.7次。临床表现可将患者分为轻度(n = 5)和重度(n = 4)肠道受累。重度组患者有更严重的消化症状,但也有更早出现的中性粒细胞减少(中位数0.3岁对1.5岁,P =0.046),且在随访期间中性粒细胞计数(NC)有降低趋势,因消化症状(中位数每年0.6次对0.05次,P =0.012)和感染(中位数每年0.8次对0.2次,P =0.014)导致的急性住院次数更多(中位数每年1.3次对0.2次,P =0.014)。治疗方法包括使用粒细胞集落刺激因子(G-CSF)和复方新诺明(n = 7)、5-氨基水杨酸(n = 2)、富含抗炎细胞因子转化生长因子-β(TGF-β)的聚合物溶液(n = 4,“重度”组)以及免疫调节治疗(n = 1)。总之,感染和IBD在GSD1B中是罕见但严重的并发症。重度IBD组中性粒细胞减少比轻度IBD组更常见。采用特定抗炎溶液的饮食治疗对这些患者似乎特别合适。